Research programme: interleukin-6 inhibitors - Y's Therapeutics

Drug Profile

Research programme: interleukin-6 inhibitors - Y's Therapeutics

Alternative Names: Anfil6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ys Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis
  • Discontinued Crohn's disease; Psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Rheumatoid-arthritis in Japan (PO)
  • 28 Feb 2011 Early research is ongoing in Japan
  • 28 Jul 2004 Discontinued - Preclinical for Crohn's disease in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top